All Stories

  1. A disturbance of lipid synthesis causes demyelinating disease
  2. Ldlr-/-.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody
  3. The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed PMP22
  4. Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury
  5. Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
  6. The development and properties of a new antibody that blocks the terminal complement system.
  7. Safety and efficacy of C1-inhibitor in traumatic brain injury (CIAO@TBI): study protocol for a randomized, placebo-controlled, multi-center trial
  8. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis
  9. Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis
  10. TUB gene expression in hypothalamus and adipose tissue and its association with obesity in humans
  11. Deregulated expression ofEZH2in congenital brainstem disconnection
  12. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator
  13. Aberrant expression of miR-218 and miR-204 in human mesial temporal lobe epilepsy and hippocampal sclerosis-Convergence on axonal guidance
  14. The microRNA-15 family inhibits the TGFβ-pathway in the heart
  15. Inhibition of the Membrane Attack Complex of the Complement System Reduces Secondary Neuroaxonal Loss and Promotes Neurologic Recovery after Traumatic Brain Injury in Mice
  16. Traumatic Brain Injury in Rats Induces Lung Injury and Systemic Immune Suppression
  17. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression
  18. Glucocorticoid-induced Changes in Gene Expression of Airway Smooth Muscle in Patients with Asthma
  19. MicroRNA-146a: A Key Regulator of Astrocyte-Mediated Inflammatory Response
  20. Ultrastructural Localization and Expression of TRPM1 in the Human Retina
  21. A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy
  22. Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development
  23. Impairment of the tRNA-splicing endonuclease subunit 54 (tsen54) gene causes neurological abnormalities and larval death in zebrafish models of pontocerebellar hypoplasia
  24. Silencing the Expression of Ras Family GTPase Homologues Decreases Inflammation and Joint Destruction in Experimental Arthritis
  25. Male Infertility
  26. Induction of sodium channel Nax (SCN7A) expression in rat and human hippocampus in temporal lobe epilepsy
  27. In vivo efficacy and off-target effects of Locked Nucleic Acid (LNA) and Unlocked Nucleic Acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts
  28. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy
  29. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo
  30. Embryonic stem cell-like cells derived from adult human testis
  31. Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A
  32. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4′-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer
  33. The Therapeutic Potential of LNA-modified siRNAs: Reduction of Off-target Effects by Chemical Modification of the siRNA Sequence
  34. tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia
  35. Evaluation of locked nucleic acid–modified small interfering RNA in vitro and in vivo
  36. Scavenger Receptor Classes A and B: Their Roles in Atherogenesis and the Metabolism of Modified LDL and HDL
  37. Evaluation of LNA-Modified DNAzymes Targeting a Single Nucleotide Polymorphism in the Large Subunit of RNA Polymerase II
  38. On the in vitro and in vivo Properties of Four Locked Nucleic Acid Nucleotides Incorporated into an Anti-H-Ras Antisense Oligonucleotide
  39. Killing cancer by targeting genes that cancer cells have lost: Allele-specific inhibition, a novel approach to the treatment of genetic disorders
  40. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides
  41. Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition
  42. [23] Targeted delivery of antisense oligonucleotides to parenchymal liver cells in vivo
  43. Scavenger Receptor BI Mediates the Selective Uptake of Oxidized Cholesterol Esters by Rat Liver
  44. In Vivo Regulation of Scavenger Receptor BI and the Selective Uptake of High Density Lipoprotein Cholesteryl Esters in Rat Liver Parenchymal and Kupffer Cells
  45. Scavenger receptor B1 (SR-B1) substrates inhibit the selective uptake of high-density-lipoprotein cholesteryl esters by rat parenchymal liver cells
  46. Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells
  47. LDL receptor-independent and -dependent uptake of lipoproteins
  48. Interactions between the Cytosolic Components p47 and p67 of the Human Neutrophil NADPH Oxidase That Are Not Required for Activation in the Cell-free System
  49. Production of senescent cells ofSaccharomyces cerevisiae by centrifugal elutriation